| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Indians, North American | 139 | 2022 | 511 | 8.880 |
Why?
|
| Cardiovascular Diseases | 55 | 2024 | 346 | 3.630 |
Why?
|
| Diabetes Mellitus, Type 2 | 32 | 2021 | 322 | 2.690 |
Why?
|
| Diabetes Mellitus | 28 | 2023 | 207 | 2.410 |
Why?
|
| Hypertension | 34 | 2023 | 304 | 1.970 |
Why?
|
| Metabolic Syndrome | 9 | 2014 | 77 | 1.760 |
Why?
|
| Risk Factors | 89 | 2024 | 2010 | 1.730 |
Why?
|
| Blood Glucose | 26 | 2017 | 300 | 1.690 |
Why?
|
| Middle Aged | 139 | 2021 | 6817 | 1.640 |
Why?
|
| Male | 159 | 2023 | 12869 | 1.470 |
Why?
|
| Aged | 108 | 2024 | 5166 | 1.450 |
Why?
|
| Female | 160 | 2023 | 14462 | 1.410 |
Why?
|
| Blood Pressure | 28 | 2019 | 351 | 1.370 |
Why?
|
| Hypertrophy, Left Ventricular | 22 | 2017 | 37 | 1.300 |
Why?
|
| Obesity | 30 | 2017 | 650 | 1.280 |
Why?
|
| Humans | 180 | 2024 | 26826 | 1.200 |
Why?
|
| Diet | 7 | 2019 | 223 | 1.130 |
Why?
|
| Albuminuria | 12 | 2017 | 23 | 1.030 |
Why?
|
| Adult | 66 | 2024 | 7382 | 1.010 |
Why?
|
| Prevalence | 42 | 2019 | 472 | 0.970 |
Why?
|
| Skin Aging | 4 | 2016 | 8 | 0.860 |
Why?
|
| Botulinum Toxins, Type A | 4 | 2016 | 8 | 0.860 |
Why?
|
| United States | 49 | 2019 | 2032 | 0.860 |
Why?
|
| Insulin Resistance | 10 | 2019 | 165 | 0.840 |
Why?
|
| Coronary Disease | 7 | 2012 | 118 | 0.830 |
Why?
|
| Body Mass Index | 19 | 2016 | 386 | 0.810 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2019 | 63 | 0.780 |
Why?
|
| Adolescent | 36 | 2024 | 2957 | 0.760 |
Why?
|
| Apolipoproteins B | 3 | 2012 | 18 | 0.730 |
Why?
|
| Oklahoma | 26 | 2021 | 973 | 0.720 |
Why?
|
| Diabetes Complications | 13 | 2012 | 66 | 0.720 |
Why?
|
| Longitudinal Studies | 30 | 2019 | 400 | 0.710 |
Why?
|
| Incidence | 26 | 2022 | 545 | 0.690 |
Why?
|
| Leukocytes | 8 | 2016 | 67 | 0.680 |
Why?
|
| Dyslipidemias | 4 | 2024 | 31 | 0.650 |
Why?
|
| Atherosclerosis | 9 | 2022 | 91 | 0.640 |
Why?
|
| Quantitative Trait Loci | 9 | 2014 | 53 | 0.640 |
Why?
|
| Young Adult | 29 | 2024 | 2581 | 0.640 |
Why?
|
| Glycated Hemoglobin A | 8 | 2011 | 64 | 0.640 |
Why?
|
| Cohort Studies | 34 | 2021 | 857 | 0.620 |
Why?
|
| Proportional Hazards Models | 20 | 2022 | 213 | 0.620 |
Why?
|
| Neuromuscular Agents | 2 | 2015 | 4 | 0.610 |
Why?
|
| Biomarkers | 14 | 2022 | 733 | 0.600 |
Why?
|
| Stroke | 6 | 2023 | 233 | 0.580 |
Why?
|
| Prospective Studies | 23 | 2024 | 1216 | 0.550 |
Why?
|
| Echocardiography | 18 | 2012 | 107 | 0.550 |
Why?
|
| Apolipoprotein C-III | 3 | 2012 | 12 | 0.540 |
Why?
|
| Insulin | 11 | 2019 | 310 | 0.530 |
Why?
|
| Telomere | 5 | 2016 | 28 | 0.530 |
Why?
|
| Genetic Variation | 7 | 2019 | 229 | 0.520 |
Why?
|
| Life Style | 5 | 2019 | 83 | 0.520 |
Why?
|
| Genetic Linkage | 7 | 2019 | 92 | 0.510 |
Why?
|
| Self Concept | 2 | 2015 | 52 | 0.500 |
Why?
|
| Cross-Sectional Studies | 16 | 2016 | 910 | 0.490 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 89 | 0.490 |
Why?
|
| Aged, 80 and over | 23 | 2019 | 1927 | 0.490 |
Why?
|
| Ventricular Function, Left | 9 | 2019 | 100 | 0.490 |
Why?
|
| Apolipoprotein A-I | 2 | 2012 | 38 | 0.480 |
Why?
|
| Heart Ventricles | 10 | 2019 | 127 | 0.480 |
Why?
|
| Glomerular Filtration Rate | 7 | 2022 | 48 | 0.480 |
Why?
|
| C-Reactive Protein | 8 | 2019 | 93 | 0.460 |
Why?
|
| Motor Activity | 2 | 2012 | 146 | 0.460 |
Why?
|
| Dietary Fats | 3 | 2014 | 55 | 0.450 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2014 | 35 | 0.440 |
Why?
|
| Telomere Homeostasis | 4 | 2019 | 10 | 0.440 |
Why?
|
| Receptors, Nicotinic | 4 | 2014 | 10 | 0.440 |
Why?
|
| Smoking | 14 | 2016 | 465 | 0.430 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2004 | 42 | 0.420 |
Why?
|
| Pediatric Obesity | 1 | 2014 | 72 | 0.420 |
Why?
|
| Antihypertensive Agents | 6 | 2013 | 57 | 0.420 |
Why?
|
| Arizona | 19 | 2013 | 38 | 0.420 |
Why?
|
| Risk Assessment | 13 | 2016 | 587 | 0.410 |
Why?
|
| Postmenopause | 2 | 2004 | 83 | 0.410 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2019 | 654 | 0.410 |
Why?
|
| Population Surveillance | 9 | 2015 | 85 | 0.410 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2019 | 537 | 0.410 |
Why?
|
| Prediabetic State | 3 | 2023 | 10 | 0.410 |
Why?
|
| Electrocardiography | 9 | 2010 | 391 | 0.390 |
Why?
|
| Health Surveys | 3 | 2010 | 77 | 0.390 |
Why?
|
| Kidney Diseases | 5 | 2013 | 59 | 0.380 |
Why?
|
| Glucose Intolerance | 7 | 2012 | 22 | 0.380 |
Why?
|
| Diabetic Nephropathies | 4 | 2017 | 19 | 0.370 |
Why?
|
| Follow-Up Studies | 20 | 2014 | 980 | 0.360 |
Why?
|
| Heart | 5 | 2015 | 219 | 0.350 |
Why?
|
| Aging | 9 | 2022 | 945 | 0.350 |
Why?
|
| Lipoproteins | 4 | 2005 | 95 | 0.350 |
Why?
|
| Myocardium | 4 | 2019 | 171 | 0.350 |
Why?
|
| Cholesterol, LDL | 9 | 2011 | 64 | 0.340 |
Why?
|
| North Dakota | 14 | 2013 | 15 | 0.330 |
Why?
|
| Prognosis | 18 | 2017 | 759 | 0.320 |
Why?
|
| Age Distribution | 8 | 2010 | 70 | 0.320 |
Why?
|
| Kidney | 4 | 2015 | 275 | 0.320 |
Why?
|
| Predictive Value of Tests | 14 | 2014 | 472 | 0.320 |
Why?
|
| Sex Factors | 12 | 2019 | 445 | 0.310 |
Why?
|
| Cerebral Infarction | 1 | 2008 | 26 | 0.310 |
Why?
|
| Genome-Wide Association Study | 7 | 2019 | 226 | 0.310 |
Why?
|
| Odds Ratio | 8 | 2017 | 230 | 0.310 |
Why?
|
| Phenotype | 13 | 2014 | 665 | 0.310 |
Why?
|
| Heart Diseases | 4 | 2014 | 68 | 0.300 |
Why?
|
| Apolipoproteins | 1 | 2008 | 21 | 0.300 |
Why?
|
| South Dakota | 14 | 2013 | 20 | 0.300 |
Why?
|
| Genetics, Population | 5 | 2019 | 72 | 0.300 |
Why?
|
| Neoplasms | 5 | 2021 | 755 | 0.290 |
Why?
|
| Fasting | 8 | 2021 | 77 | 0.280 |
Why?
|
| Nutritional Status | 1 | 2007 | 73 | 0.280 |
Why?
|
| Lipoproteins, HDL | 2 | 2011 | 41 | 0.270 |
Why?
|
| Carotid Arteries | 3 | 2014 | 52 | 0.270 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2017 | 20 | 0.260 |
Why?
|
| Visually Impaired Persons | 1 | 2005 | 5 | 0.260 |
Why?
|
| Hyperlipidemias | 5 | 2011 | 36 | 0.260 |
Why?
|
| Heart Failure | 4 | 2017 | 234 | 0.260 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 298 | 0.260 |
Why?
|
| Cosmetic Techniques | 2 | 2016 | 3 | 0.260 |
Why?
|
| Carotid Artery Diseases | 4 | 2014 | 37 | 0.250 |
Why?
|
| Fibrinogen | 6 | 2012 | 50 | 0.250 |
Why?
|
| Eye Diseases | 1 | 2005 | 31 | 0.250 |
Why?
|
| Vision Disorders | 1 | 2005 | 38 | 0.250 |
Why?
|
| Genotype | 13 | 2019 | 442 | 0.250 |
Why?
|
| Homeostasis | 2 | 2019 | 114 | 0.250 |
Why?
|
| Sex Characteristics | 4 | 2010 | 162 | 0.250 |
Why?
|
| Socioeconomic Factors | 5 | 2015 | 242 | 0.250 |
Why?
|
| Apolipoproteins C | 1 | 2005 | 4 | 0.250 |
Why?
|
| Mass Screening | 4 | 2023 | 141 | 0.240 |
Why?
|
| Lipids | 8 | 2022 | 195 | 0.240 |
Why?
|
| Linear Models | 8 | 2015 | 201 | 0.240 |
Why?
|
| Metabolome | 2 | 2016 | 64 | 0.240 |
Why?
|
| Aorta | 3 | 2015 | 123 | 0.230 |
Why?
|
| Sex Distribution | 7 | 2009 | 76 | 0.230 |
Why?
|
| Lod Score | 8 | 2014 | 36 | 0.220 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2024 | 44 | 0.220 |
Why?
|
| Energy Metabolism | 2 | 2019 | 178 | 0.210 |
Why?
|
| Stroke Volume | 9 | 2017 | 111 | 0.210 |
Why?
|
| Pedigree | 9 | 2014 | 153 | 0.210 |
Why?
|
| Triglycerides | 5 | 2023 | 117 | 0.200 |
Why?
|
| Hypolipidemic Agents | 3 | 2011 | 20 | 0.200 |
Why?
|
| Echocardiography, Doppler | 7 | 2017 | 21 | 0.200 |
Why?
|
| Cerebrovascular Disorders | 2 | 2016 | 46 | 0.200 |
Why?
|
| Child | 7 | 2012 | 2147 | 0.200 |
Why?
|
| Cholesterol, HDL | 4 | 2012 | 58 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 44 | 0.190 |
Why?
|
| Depression | 2 | 2016 | 211 | 0.190 |
Why?
|
| Health Promotion | 2 | 2014 | 169 | 0.190 |
Why?
|
| Health Status | 3 | 2019 | 145 | 0.180 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 918 | 0.180 |
Why?
|
| Body Weight | 3 | 2014 | 246 | 0.180 |
Why?
|
| Carotid Intima-Media Thickness | 4 | 2014 | 10 | 0.180 |
Why?
|
| Brachial Artery | 3 | 2010 | 36 | 0.180 |
Why?
|
| Heart Rate | 6 | 2019 | 374 | 0.170 |
Why?
|
| Analysis of Variance | 8 | 2012 | 388 | 0.170 |
Why?
|
| Glucose | 4 | 2021 | 191 | 0.170 |
Why?
|
| Creatinine | 6 | 2017 | 57 | 0.170 |
Why?
|
| Genetic Association Studies | 3 | 2014 | 110 | 0.170 |
Why?
|
| Double-Blind Method | 3 | 2015 | 399 | 0.170 |
Why?
|
| Sweetening Agents | 1 | 2019 | 7 | 0.170 |
Why?
|
| Hypercholesterolemia | 2 | 2011 | 17 | 0.170 |
Why?
|
| Models, Cardiovascular | 2 | 2016 | 46 | 0.160 |
Why?
|
| Chromosome Mapping | 8 | 2013 | 130 | 0.160 |
Why?
|
| Research Design | 3 | 2016 | 174 | 0.150 |
Why?
|
| Eye | 2 | 2015 | 35 | 0.150 |
Why?
|
| Cacodylic Acid | 1 | 2017 | 5 | 0.150 |
Why?
|
| Myocardial Infarction | 6 | 2012 | 342 | 0.150 |
Why?
|
| Arsenic | 1 | 2017 | 19 | 0.150 |
Why?
|
| Logistic Models | 7 | 2017 | 397 | 0.150 |
Why?
|
| Red Meat | 1 | 2017 | 2 | 0.150 |
Why?
|
| Child, Preschool | 5 | 2012 | 1091 | 0.140 |
Why?
|
| Environmental Pollutants | 1 | 2017 | 32 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2017 | 47 | 0.140 |
Why?
|
| Cadmium | 1 | 2016 | 14 | 0.140 |
Why?
|
| Meat | 1 | 2016 | 10 | 0.140 |
Why?
|
| Alcohol Drinking | 6 | 2016 | 162 | 0.140 |
Why?
|
| Mannose-Binding Lectin | 2 | 2009 | 3 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2014 | 15 | 0.140 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 5 | 0.140 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2005 | 57 | 0.130 |
Why?
|
| Facial Muscles | 1 | 2016 | 7 | 0.130 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2016 | 3 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2016 | 2264 | 0.130 |
Why?
|
| Vascular Stiffness | 1 | 2016 | 41 | 0.130 |
Why?
|
| Cause of Death | 5 | 2015 | 66 | 0.130 |
Why?
|
| Body Composition | 4 | 2007 | 260 | 0.130 |
Why?
|
| Sinus of Valsalva | 1 | 2015 | 12 | 0.130 |
Why?
|
| Aortic Aneurysm | 1 | 2015 | 15 | 0.130 |
Why?
|
| Family | 6 | 2013 | 98 | 0.130 |
Why?
|
| Exercise | 4 | 2016 | 451 | 0.130 |
Why?
|
| Age Factors | 5 | 2016 | 716 | 0.120 |
Why?
|
| Models, Genetic | 3 | 2010 | 123 | 0.120 |
Why?
|
| Gene Frequency | 5 | 2014 | 182 | 0.120 |
Why?
|
| Potassium, Dietary | 1 | 2015 | 1 | 0.120 |
Why?
|
| Sodium, Dietary | 1 | 2015 | 2 | 0.120 |
Why?
|
| Survival Rate | 5 | 2007 | 406 | 0.120 |
Why?
|
| Obesity, Abdominal | 1 | 2014 | 4 | 0.120 |
Why?
|
| Anticholesteremic Agents | 2 | 2011 | 13 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 19 | 0.120 |
Why?
|
| Epoxide Hydrolases | 1 | 2014 | 1 | 0.110 |
Why?
|
| Amputation | 2 | 2004 | 42 | 0.110 |
Why?
|
| Cholesterol | 4 | 2024 | 182 | 0.110 |
Why?
|
| Lipoprotein(a) | 2 | 2005 | 8 | 0.110 |
Why?
|
| Ultrasonography | 7 | 2013 | 228 | 0.110 |
Why?
|
| Adaptation, Physiological | 2 | 2012 | 158 | 0.110 |
Why?
|
| Telomere Shortening | 1 | 2013 | 4 | 0.110 |
Why?
|
| Fatty Acids | 2 | 2023 | 198 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2013 | 75 | 0.110 |
Why?
|
| Lung | 2 | 2014 | 349 | 0.110 |
Why?
|
| Infant | 2 | 2014 | 957 | 0.110 |
Why?
|
| Carotid Stenosis | 1 | 2013 | 24 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2007 | 747 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2014 | 87 | 0.110 |
Why?
|
| Body Height | 3 | 2015 | 58 | 0.110 |
Why?
|
| Multigene Family | 1 | 2012 | 50 | 0.100 |
Why?
|
| Time Factors | 5 | 2019 | 1562 | 0.100 |
Why?
|
| Diabetic Angiopathies | 2 | 2004 | 47 | 0.100 |
Why?
|
| Age of Onset | 2 | 2012 | 68 | 0.100 |
Why?
|
| Heart Atria | 5 | 2017 | 171 | 0.100 |
Why?
|
| Cultural Characteristics | 1 | 2012 | 27 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 40 | 0.100 |
Why?
|
| Myocardial Contraction | 3 | 2007 | 60 | 0.100 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2012 | 1 | 0.100 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2007 | 43 | 0.100 |
Why?
|
| Aorta, Thoracic | 1 | 2012 | 49 | 0.100 |
Why?
|
| Weight Loss | 1 | 2012 | 72 | 0.100 |
Why?
|
| Case-Control Studies | 6 | 2012 | 700 | 0.100 |
Why?
|
| Respiratory Function Tests | 1 | 2011 | 26 | 0.100 |
Why?
|
| Systole | 6 | 2006 | 24 | 0.100 |
Why?
|
| Anthropometry | 2 | 2014 | 94 | 0.090 |
Why?
|
| Comorbidity | 5 | 2015 | 252 | 0.090 |
Why?
|
| Hyperbilirubinemia | 1 | 2011 | 1 | 0.090 |
Why?
|
| Reference Values | 2 | 2012 | 198 | 0.090 |
Why?
|
| Bilirubin | 1 | 2011 | 11 | 0.090 |
Why?
|
| Health Behavior | 1 | 2012 | 154 | 0.090 |
Why?
|
| China | 1 | 2010 | 53 | 0.090 |
Why?
|
| Brain Ischemia | 1 | 2011 | 80 | 0.090 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2010 | 4 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2014 | 843 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 118 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2011 | 77 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2007 | 16 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2011 | 77 | 0.090 |
Why?
|
| Waist-Hip Ratio | 2 | 2012 | 8 | 0.090 |
Why?
|
| Disease Progression | 4 | 2017 | 450 | 0.090 |
Why?
|
| Molecular Motor Proteins | 1 | 2010 | 12 | 0.090 |
Why?
|
| Macular Degeneration | 1 | 2011 | 79 | 0.090 |
Why?
|
| Body Size | 2 | 2012 | 30 | 0.090 |
Why?
|
| Myosin Heavy Chains | 1 | 2010 | 21 | 0.090 |
Why?
|
| Sphingolipids | 2 | 2022 | 20 | 0.080 |
Why?
|
| Uric Acid | 1 | 2009 | 6 | 0.080 |
Why?
|
| Hyperuricemia | 1 | 2009 | 2 | 0.080 |
Why?
|
| Dilatation, Pathologic | 2 | 2015 | 11 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 34 | 0.080 |
Why?
|
| American Native Continental Ancestry Group | 1 | 2009 | 22 | 0.080 |
Why?
|
| Social Behavior | 1 | 2009 | 52 | 0.080 |
Why?
|
| Adiposity | 3 | 2017 | 87 | 0.080 |
Why?
|
| Lipoproteins, LDL | 2 | 2024 | 36 | 0.080 |
Why?
|
| Principal Component Analysis | 3 | 2005 | 49 | 0.080 |
Why?
|
| Tobacco Use Disorder | 1 | 2010 | 115 | 0.080 |
Why?
|
| Manometry | 3 | 2015 | 36 | 0.070 |
Why?
|
| Immunoassay | 1 | 2008 | 35 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 2008 | 90 | 0.070 |
Why?
|
| Ventricular Dysfunction | 1 | 2007 | 6 | 0.070 |
Why?
|
| Hemodynamics | 4 | 2011 | 220 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2023 | 263 | 0.070 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2006 | 22 | 0.070 |
Why?
|
| Morbidity | 2 | 2019 | 56 | 0.070 |
Why?
|
| Risk | 2 | 2019 | 133 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2005 | 246 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 2007 | 101 | 0.070 |
Why?
|
| Asthma | 1 | 2007 | 57 | 0.070 |
Why?
|
| Cardiomegaly | 1 | 2006 | 18 | 0.070 |
Why?
|
| Atrial Function, Left | 1 | 2005 | 4 | 0.070 |
Why?
|
| ROC Curve | 3 | 2016 | 139 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 445 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2016 | 186 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2009 | 508 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2009 | 209 | 0.060 |
Why?
|
| Mortality | 3 | 2015 | 43 | 0.060 |
Why?
|
| Blood Viscosity | 1 | 2005 | 10 | 0.060 |
Why?
|
| Visual Acuity | 1 | 2005 | 106 | 0.060 |
Why?
|
| Hysterectomy | 1 | 2005 | 80 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2009 | 2433 | 0.060 |
Why?
|
| Metabolomics | 2 | 2016 | 79 | 0.060 |
Why?
|
| Alleles | 2 | 2019 | 345 | 0.060 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2004 | 12 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2004 | 150 | 0.060 |
Why?
|
| North Carolina | 1 | 2023 | 16 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2008 | 27 | 0.060 |
Why?
|
| Oxygen Consumption | 2 | 2019 | 173 | 0.060 |
Why?
|
| Diabetic Retinopathy | 1 | 2005 | 108 | 0.060 |
Why?
|
| Rheumatic Heart Disease | 1 | 2003 | 4 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 144 | 0.050 |
Why?
|
| Leg | 1 | 2004 | 131 | 0.050 |
Why?
|
| Haplotypes | 2 | 2014 | 279 | 0.050 |
Why?
|
| Haptoglobins | 1 | 2002 | 21 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2015 | 66 | 0.050 |
Why?
|
| Midwestern United States | 3 | 2009 | 38 | 0.050 |
Why?
|
| Ventricular Remodeling | 2 | 2015 | 31 | 0.050 |
Why?
|
| Australia | 1 | 2022 | 21 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 357 | 0.050 |
Why?
|
| Gallbladder Diseases | 1 | 2002 | 3 | 0.050 |
Why?
|
| Acanthosis Nigricans | 1 | 2002 | 4 | 0.050 |
Why?
|
| Glycerophospholipids | 1 | 2022 | 14 | 0.050 |
Why?
|
| Hyperinsulinism | 1 | 2002 | 15 | 0.050 |
Why?
|
| Apoproteins | 1 | 2002 | 3 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 262 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2002 | 57 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2002 | 58 | 0.050 |
Why?
|
| Linkage Disequilibrium | 2 | 2012 | 107 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 213 | 0.050 |
Why?
|
| Hypertrophy | 2 | 2014 | 37 | 0.050 |
Why?
|
| Models, Biological | 2 | 2019 | 446 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2007 | 276 | 0.050 |
Why?
|
| Carotid Artery, Common | 2 | 2011 | 10 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2011 | 6 | 0.040 |
Why?
|
| Diastole | 3 | 2005 | 22 | 0.040 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2005 | 21 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2011 | 118 | 0.040 |
Why?
|
| Hypoglycemic Agents | 2 | 2011 | 105 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2009 | 12 | 0.040 |
Why?
|
| Smoking Prevention | 2 | 2012 | 87 | 0.040 |
Why?
|
| Microsatellite Repeats | 2 | 2008 | 55 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 802 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2008 | 12 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2016 | 15 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2016 | 18 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 63 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2016 | 21 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 94 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 18 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 73 | 0.030 |
Why?
|
| Steroids | 1 | 2016 | 54 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 152 | 0.030 |
Why?
|
| Amino Acids | 1 | 2016 | 80 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2015 | 9 | 0.030 |
Why?
|
| Forehead | 1 | 2015 | 2 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 250 | 0.030 |
Why?
|
| Isoflavones | 1 | 2014 | 8 | 0.030 |
Why?
|
| Overweight | 2 | 2006 | 110 | 0.030 |
Why?
|
| Microtubule Proteins | 1 | 2014 | 3 | 0.030 |
Why?
|
| Headache | 1 | 2015 | 30 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2014 | 16 | 0.030 |
Why?
|
| Hematoma | 1 | 2015 | 26 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 22 | 0.030 |
Why?
|
| Phosphatidylcholines | 1 | 2014 | 41 | 0.030 |
Why?
|
| Energy Intake | 1 | 2015 | 67 | 0.030 |
Why?
|
| Blood Flow Velocity | 2 | 2007 | 63 | 0.030 |
Why?
|
| Educational Status | 2 | 2005 | 110 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2014 | 42 | 0.030 |
Why?
|
| Body Fat Distribution | 1 | 2014 | 15 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 586 | 0.030 |
Why?
|
| Vital Capacity | 1 | 2014 | 5 | 0.030 |
Why?
|
| Spirometry | 1 | 2014 | 8 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2014 | 95 | 0.030 |
Why?
|
| Heredity | 1 | 2013 | 2 | 0.030 |
Why?
|
| Peptides | 1 | 2016 | 280 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2014 | 12 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 36 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 129 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2014 | 30 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2003 | 77 | 0.030 |
Why?
|
| Algorithms | 2 | 2006 | 419 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 184 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2013 | 121 | 0.030 |
Why?
|
| Community Participation | 1 | 2012 | 25 | 0.030 |
Why?
|
| Population | 1 | 2012 | 3 | 0.030 |
Why?
|
| Pain | 1 | 2015 | 252 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 7 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2012 | 118 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 2 | 2003 | 84 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 56 | 0.020 |
Why?
|
| Tunica Media | 1 | 2011 | 3 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2011 | 9 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2011 | 4 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 262 | 0.020 |
Why?
|
| United States Indian Health Service | 1 | 2011 | 14 | 0.020 |
Why?
|
| Sunlight | 1 | 2011 | 10 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 601 | 0.020 |
Why?
|
| Vitamins | 1 | 2011 | 22 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2011 | 29 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2010 | 1 | 0.020 |
Why?
|
| Fibric Acids | 1 | 2010 | 2 | 0.020 |
Why?
|
| Epidemiologic Research Design | 1 | 2010 | 10 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 203 | 0.020 |
Why?
|
| Azetidines | 1 | 2010 | 6 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 17 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 163 | 0.020 |
Why?
|
| Pulse | 1 | 2010 | 4 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 58 | 0.020 |
Why?
|
| Radial Artery | 1 | 2010 | 21 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 108 | 0.020 |
Why?
|
| Carrier State | 1 | 2009 | 8 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 75 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2009 | 15 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2010 | 221 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2009 | 13 | 0.020 |
Why?
|
| Employment | 1 | 2009 | 45 | 0.020 |
Why?
|
| Receptors, Adiponectin | 1 | 2008 | 5 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2008 | 13 | 0.020 |
Why?
|
| Registries | 1 | 2011 | 383 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2012 | 465 | 0.020 |
Why?
|
| Family Health | 1 | 2008 | 71 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2008 | 8 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2007 | 30 | 0.020 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2007 | 3 | 0.020 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2007 | 1 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2007 | 16 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 26 | 0.020 |
Why?
|
| Retina | 1 | 2011 | 421 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2007 | 36 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2007 | 67 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2007 | 50 | 0.020 |
Why?
|
| Genomics | 1 | 2008 | 116 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2007 | 109 | 0.020 |
Why?
|
| Oxygen | 1 | 2007 | 218 | 0.020 |
Why?
|
| Sclerosis | 1 | 2005 | 3 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2005 | 17 | 0.020 |
Why?
|
| Calcinosis | 1 | 2005 | 23 | 0.020 |
Why?
|
| Reproductive History | 1 | 2005 | 8 | 0.020 |
Why?
|
| Marital Status | 1 | 2005 | 16 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 2005 | 11 | 0.020 |
Why?
|
| Retinal Hemorrhage | 1 | 2005 | 7 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2005 | 30 | 0.020 |
Why?
|
| DNA | 1 | 2007 | 365 | 0.020 |
Why?
|
| Photography | 1 | 2005 | 19 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 42 | 0.020 |
Why?
|
| Menopause | 1 | 2005 | 28 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 14 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2005 | 7 | 0.020 |
Why?
|
| Aneurysm | 1 | 2005 | 25 | 0.020 |
Why?
|
| Hematocrit | 1 | 2005 | 26 | 0.020 |
Why?
|
| Cultural Diversity | 1 | 2005 | 18 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 36 | 0.020 |
Why?
|
| Income | 1 | 2005 | 38 | 0.020 |
Why?
|
| Retinal Vessels | 1 | 2005 | 71 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2005 | 163 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2005 | 86 | 0.010 |
Why?
|
| Life Tables | 1 | 2004 | 6 | 0.010 |
Why?
|
| Body Constitution | 1 | 2003 | 11 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2004 | 26 | 0.010 |
Why?
|
| Organ Size | 1 | 2004 | 83 | 0.010 |
Why?
|
| Survivors | 1 | 2004 | 36 | 0.010 |
Why?
|
| Mitral Valve Stenosis | 1 | 2003 | 2 | 0.010 |
Why?
|
| Sample Size | 1 | 2003 | 17 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 43 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 93 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 2002 | 16 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2002 | 12 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2002 | 64 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2002 | 28 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2002 | 89 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 279 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 80 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2002 | 68 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 140 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2005 | 398 | 0.010 |
Why?
|